



July 27, 2018

DOCUMENT AMENDMENT

Please note the following amendments to the document entitled “Canadian Society of Forensic Science Drugs and Driving Committee (DDC) Drug Screening Equipment – Oral Fluid Standards and Evaluation Procedures”, effective November 1st, 2017.

Amendment to the Evaluation Procedures for Standard 2:

In this amendment, the current statement:

Twenty (20) separate tests of THC, cocaine and methamphetamine-negative oral fluid shall be performed. All of these tests shall produce a negative result by the drug screening equipment. Synthetic oral fluid shall be used to perform these tests according to the formulation detailed in Appendix B.

will be replaced by the following statement:

Twenty (20) separate tests of THC, cocaine and methamphetamine-negative oral fluid shall be performed. All of these tests shall produce a negative result by the drug screening equipment. Synthetic oral fluid shall be used to perform these tests according to the formulation detailed in Appendix B. The DDC reserves the right to conduct additional testing using collected human oral fluid.

Please note that this amendment applies equally to all references to synthetic oral fluid throughout the document. The purpose of the above-noted amendment is to reflect the variation possible between actual human oral fluid and synthetic oral fluid.

Amendment to the Evaluation Procedures for Standard 4:

In this amendment, the current statement:

Individual synthetic oral fluid solutions shall be prepared to 25%, 60%, 140% and 175% of the cut-off concentrations for each of the individual specific drugs of interest. Concentrations shall be verified.

will be replaced by the following statement:

Individual synthetic oral fluid solutions shall be prepared to 25%, 60%, 140% and 175% of the cut-off concentrations for each of the individual specific drugs of interest. Cerilliant® standards for methamphetamine (product # M-009) cocaine (product # C-008) and THC (product # T-005) will be used unless otherwise stated. Concentrations shall be verified.”

The purpose of the above-noted amendment is to provide clarification as to the specifics of laboratory testing for specific drugs of interest.

Amendment to the Evaluation Procedures for Standard 27:

In this amendment, the current statement:

Manufacturers shall submit documentation detailing the reliability (i.e., within 10% of the target) of the oral fluid volume collected, and at which the operator is notified of sufficient volume.

will be replaced by the following statement:

Manufacturers shall submit documentation detailing the reliability of the oral fluid volume collected, and at which the operator is notified of sufficient volume. For laboratory testing purposes, manufacturers must indicate the required volume of oral fluid for analysis.

The purposes of the above-noted amendment are to 1) eliminate undue stringency in the evaluation procedures given the generally low volumes of oral fluid required for analysis, and 2) notify manufacturers of required information.